Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers
Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs.
Stocktwits
Valion Bio Appoints Melinda Lackey as General Counsel
Valion Bio Appoints Melinda Lackey as General Counsel Valion Bio Appoints Melinda Lackey as General Counsel PR Newswire SAN ANTONIO, May 4, 2026 Seasoned Biopharmaceutical Attorney with Deep IP...
PR Newswire
These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?
iCoreConnect, BioAffinity and Alaunos Therapeutics posted strong gains last week amid heavy trading volume.